Abrégé

The present invention provides Interleukin-13 Receptor Subunit Alpha-2 (IL13Rα2) targeting moieties, and CAR comprising them, which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment and prevention of IL13Rα2-positive cancers, such as glioblastoma or diffuse intrinsic pontine glioma.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]

Abrégé

The present invention provides a fusion protein suitable to reduce graft-versus-host and host-versus-graft reactions in allogenic transplants. Said fusion protein comprises an anti-CD3 targeting moiety and a human cytomegalovirus US6 protein.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 40/30 - Immunothérapie cellulaire caractérisée par l’expression recombinante de molécules spécifiques dans les cellules du système immunitaire
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]

Abrégé

The present invention relates to T cells expressing bispecific antibodies for BCMA and CD3 and uses thereof in the treatment of cancer, in particular cancers which overexpress BCMA antigen.

Classes IPC  ?

• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/33 - AnticorpsActivateurs de lymphocytes T
• A61K 40/42 - Antigènes associés au cancer
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

It relates to statins or their pharmaceutically acceptable salts for use in the prevention and/or treatment of splanchnic vascular dysfunctions in a patient which is a mammal wherein the prevention and/or treatment comprises inhibiting and/or reverting endothelial-to-mesenchymal transition of endothelial cells.

Classes IPC  ?

• A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
• A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 31/404 - Indoles, p. ex. pindolol
• A61K 31/47 - QuinoléinesIsoquinoléines
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires

Abrégé

The present invention relates to a CD7 targeting moiety, wherein the CD7 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CD7 retention domains, CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD7 targeting moiety. Lastly, methods of treatment of a CD7-positive cancer, preferably T-ALL are also provided.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 40/42 - Antigènes associés au cancer

Produits et services

Incubators [medical devices], incubators for newborns.

Abrégé

The present disclosure relates to a computer implemented method, system, and computer program for in silico surgical planification of a left atrial appendage occlusion (LAAO), wherein the risk of developing a device-associated thrombosis prior to a LAAO surgical intervention is evaluated. The positioning of the 3D model of the left atrial appendage occluder is determined according to anatomical characteristics of the left atrium of the patient, a first compression value and a structural simulation that provides a second compression value. The method further computes a risk score for device-induced thrombosis by analysing computational fluid dynamics calculations in conjunction with patient's medical parameters. This risk assessment aids in optimizing the positioning of the LAAO device, potentially reducing the incidence of post-operation thrombosis.

Classes IPC  ?

• A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical
• A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

It relates to Elvitegravir or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection caused by multidrug-resistant Gram-positive bacteria.

Classes IPC  ?

• A61K 31/47 - QuinoléinesIsoquinoléines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention provides methods for obtaining human induced pluripotent stem cells (hiPSC)-derived neuronal cells which are useful for the diagnosis of neurological disorders associated with the presence of neuronal antibodies. In particular, the invention provides a method for obtaining hiPSC-derived neuronal cells, wherein the method comprises culturing neuronal progenitor cells for at least three weeks in proneural medium in optimized conditions. The invention further covers the use of neuronal cells obtained by the method of the invention as a diagnostic test in neurological disorders associated with the presence of neuronal antibodies and kits comprising the same.

Classes IPC  ?

• C12N 5/0793 - Neurones

Abrégé

An instrument for transorbital endoscopic surgery is proposed. The instrument comprises a handle; a support element, the handle being movably attached, at one end, to the support element; a first arm and a second arm, each one comprising a fixing portion, which connects the arm to the support element, and an anchoring portion, which is releasably attached to the fixing portion, one of the anchoring portions being configured to be anchored to a first fissure of the orbital cavity and the other one of the anchoring portions being configured to be anchored to a second fissure of the orbital cavity, each one of the anchoring portions comprising a given curvature; a mesh, arranged between and connected to each one of the anchoring portions to gather the periorbital when the anchoring portions are anchored to the first and seconds fissures; and sensors to detect an applied pressure applied to the first and second fissures.

Classes IPC  ?

• A61B 17/02 - Instruments, dispositifs ou procédés chirurgicaux pour maintenir les blessures ouvertes, p. ex. rétracteursÉcarteurs
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures

Abrégé

Non-invasive biomarkers for the diagnosis and prognosis of portal hypertension. Advantageously, the markers allow to appropriately differentiate between the non-clinical and clinically significant portal hypertension, thus being possible a more precise management of the therapeutic protocols.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The present invention provides new therapeutic approaches for the treatment or prevention of FGFR4-expressing cancers, including those resistant to other therapies.

Classes IPC  ?

• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

Classes IPC  ?

• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale

Abrégé

The present invention relates to gene therapy for the treatment of Glutaric Aciduria type I (GA-1), wherein the treatment comprises the administration of a nucleic acid comprising an expression cassette comprising the nucleotide sequence of a chimeric promoter and the nucleotide sequence encoding for the human glutaryl-CoA dehydrogenase enzyme (GCDH). Virions, cells and pharmaceutical composition comprising said nucleic acid are also provided.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation

Abrégé

The present invention refers to the medical field. Particularly, the present invention refers to autologous/allogeneic CAR (chimeric antigen receptor)-T/NK cells for use in the treatment of invasive fungal infections.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61P 31/10 - Antifongiques
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

This application relates to steerable catheters comprising first and second steering sections that are respectively configured to steer in opposite directions within the same plane. The application also relates to a system comprising a steerable catheter as disclosed and a patch deployment device that is deployable via the catheter.

Classes IPC  ?

• A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
• A61F 2/95 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes

Abrégé

The invention relates to the use of a MiRNA panel, preferably detected in plasma, as biomarkers for the diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) and/or the prognosis of pulmonary embolism (PE). The invention also relates to a method which uses level of expression of said miRNAs to determine the diagnosis of CTEPH and/or the prognosis of EP, as well as a kit for the detection of these biomarkers in biological samples.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to a CD229 and a BCMA targeting moiety, wherein the CD229 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD229 and BCMA targeting moiety. Methods of treatment of a CD229-positive cancer, preferably Multiple Myeloma, are also provided.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

A female urine collector (1), comprising a base (2) configured to attach to the vaginal area of a patient (P) around the urethral orifice; and a collection bag (3) attached to the base configured to collect urine from the patient. Said urine collector comprises adhesive means (4) that attach the base to the collecting bag, configured to allow the removal of the collecting bag while keeping the base adhered to the patient.

Classes IPC  ?

• A61F 5/443 - Dispositifs portés par le patient pour recueillir l'urine, les selles, les menstrues ou d'autres sécrétionsDispositifs de colostomie comportant des joints d'étanchéité de type hydrocolloïde, p. ex. gels, empois d'amidon, gomme Karaya
• A61F 5/455 - Réceptacles génitaux pour recueillir l'urine ou d'autres sécrétions des organes féminins

Produits et services

Incubation units.

Produits et services

Incubation units.

Abrégé

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat

Abrégé

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer and/or for the prediction of response to anti-HER2 therapies in patients suffering from HER2+ breast cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques

Abrégé

The present invention relates to cyclic peptides of a particular formula (I), X1X2X3X4CX6X7X8PX10X11X12X13CX15X16X17P (SEQ ID NO: 1) (I), fwherein X1 to X17 take several meanings, and X1 and D-Pro at position 18 are linked by a peptide bond; which cyclic peptides are useful as antimicrobial agents. The invention also relates to particular bicyclic compounds, in which cysteines at positions 5 and 14 are crosslinked by a disulfide bond. The invention also relates to pharmaceutical compositions comprising the said peptides and to the medical applications of the peptides or of the compositions comprising them.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• A61P 31/04 - Agents antibactériens
• A61K 38/00 - Préparations médicinales contenant des peptides

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

in vitro in vitro use of DNA copy number alterations (CNAs) for predicting the response of patients with HR+/HER2− breast cancer to a treatment comprising targeted therapy, such as CDK4/6 inhibitors, and/or endocrine therapy; for the prognosis of patients with HR+/HER2− breast cancer; for monitoring patients with HR+/HER2− breast cancer; or for classifying patients with HR+/HER2− breast cancer into responder or non-responder to a treatment comprising targeted therapy, such as CDK4/6 inhibitors, and/or endocrine therapy.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

A method and a system for determining the amount of oxygen required by a user with respiratory problems are disclosed. First data about several users with respiratory problems is stored in a database. The method a) collects second data from a monitored user while (s)he is performing a test at a first location; b) computes a user’s behavioral model executing a first algorithm on the first and second data; c) collects, every period of time t1, third data of the user while (s)he is performing an activity at a second location; d) adjusts, every period of time t2, the computed user’s behavioral model using the first algorithm, providing a customized user’s behavioral model as a result; and e) computes an estimator of the quantity of oxygen to be delivered to the user by executing a second algorithm on the customized user’s behavioral model.

Classes IPC  ?

• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p. ex. ventilateursTubes trachéaux
• G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
• G06N 20/00 - Apprentissage automatique

Abrégé

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer, for the prediction of response to anti-HER2 therapies and/or for predicting survival benefit from anti-HER2 therapies

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer, for the prediction of response to anti-HER2 therapies and/or for predicting survival benefit from anti-HER2 therapies.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present invention relates to a bispecific antibody comprising an anti-CD19 single-chain fragment variable and an anti-CD3 single-chain fragment variable. The present invention also relates to T cells secreting the bispecific antibody, method of preparation of T cells secreting the bispecific antibody and uses thereof in the treatment of a hematological malignancy selected from the group consisting of lymphoma, leukemia and myeloma.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

The present invention provides a method for deciding a check-point inhibitor (ICI)-based therapy, for a patient suffering from cancer, the method comprising the steps: a) measuring the expression level of the following markers: TGFB1, ZEB1, FAP, ZEB2, GLUL, ENTPD1, GOT1, LDHA, TWIST1, and GLS, in an isolated cancerous biological tissue sample from the patient; b) determining which markers are differentially expressed; and c) classifying the sample, depending on the markers differentially expressed, in one of the following clusters: cluster 1: when ZEB1, ZEB2, ENTPD1, FAP and GLUL are up-regulated; cluster 2: when GLS is upregulated; and LDHA, GOT1, ZEB1, ZEB2 and ENTPD1 are downregulated; and cluster 3: when GOT1 is upregulated and TGFB1 and TWIST 1 are downregulated.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present inventors provide non-invasive biomarkers for the diagnosis and prognosis of portal hypertension. Advantageously, the markers of the invention also allow to appropriately differentiate between the non-clinical and clinically significant portal hypertension, thus being possible a more precise management of the therapeutic protocols.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention refers to the medical field. Particularly, the present invention refers to autologous/allogeneic CAR (chimeric antigen receptor)-T/NK cells for use in the treatment of invasive fungal infections.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire

Abrégé

The present invention refers to the medical field. Particularly, the present invention refers to autologous/allogeneic CAR (chimeric antigen receptor)-T/NK cells for use in the treatment of invasive fungal infections.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T

Abrégé

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine

Abrégé

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine

Abrégé

The present invention provides a patch deployment device, the device comprising a pusher wire having a proximal end and a distal end; a plurality of deployment wires, wherein each deployment wire: has a first end and a second end, and the first end and the second end are connected to the distal end of the pusher wire; and is configured to be in an unexpanded state when positioned and constrained within a catheter, and configured to self-expand into an expanded state when positioned beyond a distal end of the catheter and not constrained, wherein in the expanded state at least a portion of the wire is positioned substantially within a plane that is substantially perpendicular to the longitudinal axis of the pusher wire and has an asymmetric form when viewed along a direction parallel to the longitudinal axis of the pusher wire.

Classes IPC  ?

• A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical
• A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents

Abrégé

Non-invasive method for the diagnosis or screening of colorectal cancer and/or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Patch (1) for sealing an amniotic membrane, wherein the patch (1) comprises a support (11) and an adhesive (12) that is activated in presence of amniotic liquid or a wet environment. Device for placing said patch (1) comprising a cannula (2) for inserting said patch (1) in a rolled-up position, said cannula (2) being provided with a handle (3); and a dipstick (4) provided with a pusher (5), said dipstick (4) being inserted inside the cannula (2) in the use position. The patch adheres efficiently on the amniotic membrane, adapts to the elastic properties of this membrane, and by attaching only to the amnion it does not interfere with the natural sliding movements of one membrane against each other, together with the device to ensure that the patch is placed in the proper position without damaging the membrane.

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T

Abrégé

in vitro in vitro use of a Coronavirus antigen, measured in plasma, serum or blood samples obtained from the patient, for the prognosis and/or for predicting the mortality risk of patients suffering from Coronavirus infection, for predicting the response of patients suffering from Coronavirus infection to an antiviral therapy or for selecting patients suffering from Coronavirus infection for receiving an antiviral therapy.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat

Abrégé

A method and a system for determining the amount of oxygen required by a user with respiratory problems are disclosed. First data about several users with respiratory problems is stored in a database. The method a) collects second data from a monitored user while (s)he is performing a test at a first location; b) computes a user's behavioral model executing a first algorithm on the first and second data; c) collects, every period of time t1, third data of the user while (s)he is performing an activity at a second location; d) adjusts, every period of time t2, the computed user's behavioral model using the first algorithm, providing a customized user's behavioral model as a result; and e) computes an estimator of the quantity of oxygen to be delivered to the user by executing a second algorithm on the customized user's behavioral model.

Classes IPC  ?

• G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p. ex. ventilateursTubes trachéaux
• A61M 16/10 - Préparation de gaz ou vapeurs à respirer
• A61B 5/083 - Mesure du taux de métabolisme en utilisant un essai respiratoire, p. ex. mesure du taux de consommation d'oxygène
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61M 16/06 - Masques respiratoires ou pour l'anesthésie
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale

Abrégé

Methods and systems for enhancing glucose monitoring are disclosed that allow for more precise control of the glucose level by taking into account new control parameters. The disclosed methods include obtaining an initial CGM value (CGM) from a CGM sensor, obtaining a set of parameters from a wearable device, calculating an error (E) in the initial CGM value (CGM) using a regression algorithm based upon the initial CGM value and the obtained set of parameters, and calculating an enhanced CGM value (eCGM) according to the formula eCGM=CGM−E. The error (E) is calculated according to the formula: E=θ*p, wherein E is the calculated error, θ represents the data obtained from the wearable device after removing a baseline value of each wearable, and p represents regression parameters based upon an error value obtained in a training population.

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/1495 - Étalonnage ou test des sondes in vivo
• A61B 5/01 - Mesure de la température de parties du corps
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
• A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques

Abrégé

in vitroin vitro method for the prognosis of patients suffering from HER2+ breast cancer and/or for the prediction of response to anti-HER2 therapies in patients suffering from HER2+ breast cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Produits et services

Scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, signalling, detecting, testing, inspecting, life-saving and teaching apparatus and instruments; Apparatus, instruments and cables for electricity; Apparatus and instruments for transforming electricity; Apparatus and instruments for transforming electricity; Apparatus for measuring, monitoring and analyzing electricity consumption; Apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; Recorded or downloadable media; Data storage media; Data storage devices; Data storage programs; Software; Computer software, recorded; Downloadable software; Downloadable computer software for remote monitoring and analysis; Digital storage media; Magnetic data media; Optical data media; Computers and computer peripherals; Computer network-attached storage [NAS] hardware; Monitoring instruments; Application software. Surgical, medical, dental and veterinary apparatus and instruments; Orthopedic articles; Suture materials; Therapeutic and assistive devices adapted for the disabled; Medical apparatus and instruments; Diagnostic apparatus for medical purposes; Tools for medical diagnostics. Scientific and technological services, as well as related research and design services; industrial analysis, industrial research and industrial design services; Quality control and authentication; Design and development of hardware and software; Configuration of computer software; Installation of computer software; Updating, maintenance and repair of computer software; Software as a service [SaaS]; Platform as a service [PaaS]; Scientific research for medical purposes. Medical services; Animal healthcare services; Hygienic and beauty care for human beings or animals; Hospital services; Telemedicine services.

Produits et services

Scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, signalling, detecting, testing, inspecting, life-saving and teaching apparatus and instruments; Apparatus, instruments and cables for electricity; Apparatus and instruments for transforming electricity; Apparatus and instruments for transforming electricity; Apparatus for measuring, monitoring and analyzing electricity consumption; Apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; Recorded or downloadable media; Data storage media; Data storage devices; Data storage programs; Software; Computer software, recorded; Downloadable software; Downloadable computer software for remote monitoring and analysis; Digital storage media; Magnetic data media; Optical data media; Computers and computer peripherals; Computer network-attached storage [NAS] hardware; Monitoring instruments; Application software. Surgical, medical, dental and veterinary apparatus and instruments; Orthopedic articles; Suture materials; Therapeutic and assistive devices adapted for the disabled; Medical apparatus and instruments; Diagnostic apparatus for medical purposes; Tools for medical diagnostics. Scientific and technological services, as well as related research and design services; industrial analysis, industrial research and industrial design services; Quality control and authentication; Design and development of hardware and software; Configuration of computer software; Installation of computer software; Updating, maintenance and repair of computer software; Software as a service [SaaS]; Platform as a service [PaaS]; Scientific research for medical purposes. Medical services; Animal healthcare services; Hygienic and beauty care for human beings or animals; Hospital services, Telemedicine services.

Abrégé

PIKC3APIKC3A gene.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to a bispecific antibody comprising an anti-CD19 single- chain fragment variable and an anti-CD3 single-chain fragment variable. The present invention also relates to T cells secreting the bispecific antibody, method of preparation of T cells secreting the bispecific antibody and uses thereof in the treatment of a hematological malignancy selected from the group consisting of lymphoma, leukemia and myeloma.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

The present invention provides a patch deployment device, the device comprising a pusher wire having a proximal end and a distal end; a plurality of deployment wires, wherein each deployment wire: has a first end and a second end, and the first end and the second end are connected to the distal end of the pusher wire; and is configured to be in an unexpanded state when positioned and constrained within a catheter, and configured to self-expand into an expanded state when positioned beyond a distal end of the catheter and not constrained, wherein in the expanded state at least a portion of the wire is positioned substantially within a plane that is substantially perpendicular to the longitudinal axis of the pusher wire and has an asymmetric form when viewed along a direction parallel to the longitudinal axis of the pusher wire.

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

The present invention provides a patch deployment device, the device comprising a pusher wire having a proximal end and a distal end; a plurality of deployment wires, wherein each deployment wire: has a first end and a second end, and the first end and the second end are connected to the distal end of the pusher wire; and is configured to be in an unexpanded state when positioned and constrained within a catheter, and configured to self-expand into an expanded state when positioned beyond a distal end of the catheter and not constrained, wherein in the expanded state at least a portion of the wire is positioned substantially within a plane that is substantially perpendicular to the longitudinal axis of the pusher wire and has an asymmetric form when viewed along a direction parallel to the longitudinal axis of the pusher wire.

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents

Produits et services

Downloadable computer applications for sanitary services. Telemedicine services.

Abrégé

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 19/00 - Peptides hybrides
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/725 - Récepteurs de lymphocytes-T
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

Non-invasive method for the diagnosis or screening of colorectal cancer and/or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Patch (1) for sealing an amniotic membrane, wherein the patch (1) comprises a support (11) and an adhesive (12) that is activated in presence of amniotic liquid or a wet environment. Device for placing said patch (1) comprising a cannula (2) for inserting said patch (1) in a rolled-up position, said cannula (2) being provided with a handle (3); and a dipstick (4) provided with a pusher (5), said dipstick (4) being inserted inside the cannula (2) in the use position. The patch adheres efficiently on the amniotic membrane, adapts to the elastic properties of this membrane, and by attaching only to the amnion it does not interfere with the natural sliding movements of one membrane against each other, together with the device to ensure that the patch is placed in the proper position without damaging the membrane.

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 17/42 - Instruments ou procédés de gynécologie ou d'obstétrique

Abrégé

Patch (1) for sealing an amniotic membrane, wherein the patch (1) comprises a support (11) and an adhesive (12) that is activated in presence of amniotic liquid or a wet environment. Device for placing said patch (1) comprising a cannula (2) for inserting said patch (1) in a rolled-up position, said cannula (2) being provided with a handle (3); and a dipstick (4) provided with a pusher (5), said dipstick (4) being inserted inside the cannula (2) in the use position. The patch adheres efficiently on the amniotic membrane, adapts to the elastic properties of this membrane, and by attaching only to the amnion it does not interfere with the natural sliding movements of one membrane against each other, together with the device to ensure that the patch is placed in the proper position without damaging the membrane.

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 17/42 - Instruments ou procédés de gynécologie ou d'obstétrique

Abrégé

The present invention relates to a diagnostically useful carrier comprising a means for specifically capturing an antibody to a polypeptide from the group comprising squid MLC1 or squid MLC2 or a variant thereof in a sample from a subject, a method comprising the step detecting in a sample from a subject the presence or absence of an antibody to squid MLC1 or squid MLC2 and a use of the polypeptide or the carrier according to the present invention or a polypeptide binding specifically to an IgE antibody from the sample of a patient to squid MLC1 or squid MLC2 for the manufacture of a diagnostic kit, preferably for the diagnosis of allergy.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• C07K 19/00 - Peptides hybrides
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

Classes IPC  ?

• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 35/74 - Bactéries
• A61K 35/741 - Probiotiques

Abrégé

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 35/66 - Micro-organismes ou substances provenant de micro-organismes
• A61K 35/74 - Bactéries
• C12N 1/04 - Conservation des micro-organismes à l'état viable

Abrégé

The invention relates to a method, intended to be implemented using a computer system by means of management software, which consists in establishing differentiated groups of input variables in a specific manner and combining them according to valuation rules based on concretion algorithms, which establish the calculation thereof in the progression of tumour biomarker readings at different concentrations as diagnostic elements of neoplasia, together with other elements, for high specificity, varying by tumour type, history and stage. The obtained results, varying according to the tumour and the biomarkers, oscillate between sensitivities of more than 65% in stage I and II tumours, 75% in locally advanced neoplasms and 80-95% in metastasic neoplasms.

Classes IPC  ?

• G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies

Abrégé

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
• G16B 25/00 - TIC spécialement adaptées à l’hybridationTIC spécialement adaptées à l’expression de gènes ou de protéines
• G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Present invention discloses in vitroPresent invention discloses in vitro method for the diagnosis of multiple system atrophy comprising determining, in an isolated cerebrospinal fluid sample of a subject, the level of expression of one or more cytokines. It also relates to particular combinations of the levels of these cytokines that provide information for the differential diagnosis of multiple system atrophy and Parkinson's disease.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
• G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

T. cruziT. cruziT. cruzi parasite protein including pyruvate phosphate dikinase, such that the detected protein expression product can serve as potential biomarker in the context of the therapeutic response and prognosis of the disease during chronic infection.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention refers to a composition comprising uric acid for its use in the treatment of brain stroke in a patient treated by means of mechanical thrombectomy.

Classes IPC  ?

• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 38/49 - UrokinaseActivateur du plasminogène

Abrégé

The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, of the subjects to be screened with an already established expression pattern or level, wherein over expression of at least any of the above mentioned miRNAs is indicative of pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN).

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes

Abrégé

The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle

Abrégé

The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle

Abrégé

The present invention relates to a composition comprising uric acid for use in the treatment of brain stroke patients treated by means of mechanical thrombectomy.

Classes IPC  ?

• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention is based on the discovery of genetic polymorphisms that are associated with early onset of L-DOPA-induced dyskinesia (LID) and the severity of LID in patients affected of Parkinson disease (PD). In particular, the present invention relates to predictive medicine methods based on the determination of certain genetic polymorphisms, as well as kits for carrying out said methods.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention refers to an in vitro method for determining the efficacy of anti- HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to the field of medicine and provides compositions and kits-of-parts comprising a CD6 product and Imipenem, in particular for their use in a therapeutic and/or preventive method of treatment, in a mammal including a human, of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]

Abrégé

A computer implemented method to identify the ventricular arrhythmogenic substrate in myocardial scar or fibrotic tissue and computer program products A plurality of mapping points acquired from a patient are stored in a signal acquisition unit, said mapping points including a ECG signals, EGM signals and a 3D location of the EGM signals, the method comprising for a reference mapping point: a) detecting each beat present in one recorded ECG signal and identifying a beat of interest from the detected beats; b) identifying a principal EGM wave related to the identified beat of interest; c) identifying an onset and an end time landmarks of said principal EGM wave providing a primary delineated EGM signal and measuring a voltage amplitude of the primary delineated EGM signal; d) performing a further analysis of the primary delineated EGM; and e) creating a conducting channel map and a propagation map of the heart based on the result of a tagging performed during said analysis.

Classes IPC  ?

• A61B 5/04 - Mesure de signaux bioélectriques du corps ou de parties de celui-ci
• A61B 5/0452 - Détection de paramètres spécifiques du cycle de l'électrocardiogramme
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/0408 - Electrodes spécialement adaptées à cet effet
• A61B 5/042 - Electrodes spécialement adaptées à cet effet pour l'introduction dans le corps

Abrégé

The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa- miR-761, of the subjects to be screened with an already established expression pattern or level, wherein over expression of at least any of the above mentioned miRNAsis indicative of pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN).

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to cerium oxide nanoparticles useful in the treatment of hepatocellular carcinoma (HCC), said nanoparticles being cerium oxide single-crystalline nanoparticles of formula (I) NP-(A)n (I), wherein NP is a single-crystalline cerium oxide nanoparticle with a crystal diameter from 3 to 24 nm; A is a molecule selected from the group consisting of albumin, polyvinylpyrrolidone, and combinations thereof; and n is an integer from 0 to 40, and wherein if the crystal diameter of the nanoparticle is from 3 to 7 nm, then n is an integer from 1 to 12. The invention proposes also particular nanoparticles of formula (I) as conjugates, as well as pharmaceutical compositions comprising them.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/51 - Nanocapsules
• A61K 33/24 - Métaux lourdsLeurs composés
• A61P 35/00 - Agents anticancéreux
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• C01F 17/00 - Composés des métaux des terres rares

Produits et services

Diagnostic preparations; Medical preparations; Anaesthetics; Analgesics; Drug delivery agents. Anaesthetic apparatus; Anaesthesia monitoring apparatus; Diagnostic, examination, and monitoring equipment; Tools for medical diagnostics; Apparatus for drug administration; Analysers for medical use. Wholesaling, retailing in shops and sale via global computer networks of diagnostic preparations for medical purposes, medical goods, anaesthetic preparations, analgesic preparations, drug delivery agents, anaesthetic apparatus, anaesthesia monitoring apparatus, equipment for diagnosis, examination and monitoring, medical diagnosis instruments, apparatus for drug administration, analysis apparatus for medical purposes. Medical research; Scientific research; Product research and development; Research to develop new products; Conducting clinical trials for pharmaceutical products; Product testing; Scientific research; Research into new products; Laboratory services; Measurement services. Medical analysis for the diagnosis and treatment of persons; Preparation and dispensing of medications; Monitoring of patients.

Abrégé

The system comprising an internal unit (10) comprising two arrays of N transmitter and N receiver antennas (11R, 11T) for transmitting a microwave signal(s) to one or more body tissues of a patient and for detecting a scattered microwave signal(s) by said one or more body tissues; feeding and multiplexing means (12) in connection with said N transmitter and N receiver antennas (11T, 11R) and with an external computing unit (20) configured to receive said scattered microwave signal(s) and convert it/them into an image, wherein the feeding and multiplexing means (12) provide, under the control of a controller (21) of the external computing unit (20), a continuous sequential selection of different pairs of transmitter and receiver antennas (11T, 11R) to perform the transmission of the microwave signal(s) and the detection of the scattered microwave signal(s).

Classes IPC  ?

• A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
• A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The invention relates to the use of extracellular mitochondrial DNA as a quantitative biomarker for the sub-classification of patients suffering from Parkinson disease in the subgroups of familial or idiopathic Parkinson. The invention also relates to a method and to a kit for the sub-classification of patients suffering from Parkinson disease using said biomarker.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

A bioreactor for cell co-culture having at least first and second cell culture chambers which are separated by a porous membrane. The membrane has at least one sealing gasket integrated in the membrane and being integral therewith. The sealing gasket defines a closed perimeter delimiting a first cell culture area.

Classes IPC  ?

• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores

Abrégé

The present invention provides methods for diagnosing psoriatic arthritis (PsA) in an individual. Specifically, the method relates to detecting the presence or absence of an intergenic deletion between the human ADAMTS9 and MAGI1 genes. Also provided herein are methods for determining whether a subject has a risk of developing PsA. The methods described herein can be used for selecting a treatment of a subject suspected of having PsA.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G16B 25/00 - TIC spécialement adaptées à l’hybridationTIC spécialement adaptées à l’expression de gènes ou de protéines
• G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The invention relates to a method for the prognosis of hepatocellular carcinoma in an isolated sample of a subject, the method comprising providing a DNA methylation signature, said signature obtained from the qualitative and quantitative methylation analysis of 36 selected CpG sites. The invention also disclosesparticular methods in which a Mortality Index score is provided from said signature.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

Means and methods for measuring pain and adapted for calculating the level of nociception during general anesthesia or sedation from data including electroencephalogram (EEG), facial electromyogram (EMG), heart rate variability (HRV) by electrocardiogram (ECG) and plethysmography by impedance cardiography (ICG). In a preferred embodiment of this invention the parameters derived from the EEG, the HRV, the plethysmographic curve and the analgetics concentrations are either combined into one index on a scale from 0 to 100, where a high number is associated with high probability of response to noxious stimuli, while a decreasing index is associated with decreasing probability of response to noxious stimuli. Zero (0) indicates extremely low probability of response to noxious stimuli. In an alternative embodiment, only features from the EEG and ECG will be used or only features from EEG, ECG and ICG, to define the final index.

Classes IPC  ?

• A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
• A61B 5/0402 - Electrocardiographie, c. à d. ECG
• A61B 5/0476 - Electro-encéphalographie
• A61B 5/0488 - Electromyographie

Abrégé

Peptides against the external protein A (OmpA) are provided for the treatment of infections caused by Gram negative pathogens, especially Acinetobacter baumanii, Escherichia coli or Pseudomonas aeruginosa. Preferred cyclic hexapeptides comprise tryptophan, proline and arginine,and a preferred cyclic hexapeptide has the sequence c- (WPRWPR). Variants thereof with modified amino acids, D-amino acids or different order of the amino acids in the cyclic hexapeptide are also disclosed.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 7/50 - Peptides cycliques contenant au moins une liaison peptidique anormale
• C07K 14/21 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pseudomonadaceae (F)
• C07K 14/245 - Escherichia (G)
• A61K 38/12 - Peptides cycliques
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention provides methods for selecting an individual with psoriasis (Ps) or psoriatic arthritis (PsA) who should receive or who is likely to respond to a treatment with an anti-tumor necrosis factor alpha (anti-TNFα) therapy. In addition, provided herein are methods for selecting an individual with Ps or PsA who should receive or who is likely to respond to a therapy that is not an anti-TNFα therapy, e.g., a non-anti-TNFα therapy for the treatment of Ps or PsA. Specifically, the methods of the present invention relate to detecting the presence of distinct alleles of the PDE3A-SLCO1C1 locus which are associated with a clinical response to an anti-TNFα therapy or a non-anti-TNF therapy in patients with Ps or PsA.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention provides methods for predicting response to anti-TNFα biological agent treatment in a rheumatoid arthritis patient and methods for selecting a treatment for a rheumatoid arthritis patient, the methods comprising determining the level of expression of PIK3CD as a biomarker, and optionally also determining the level of expression of CX3CL1 as a second biomarker. The invention additionally provides kits for carrying out the methods described.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.

Classes IPC  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
• A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
• A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide

Abrégé

c) automatically identifying the possible channels by means of automatically obtaining candidate channels regions (CCR), dilating the perimeters of the well-defined zone (S) patches. The method includes embodiments for a layered approach, an EAM polygonal mesh approach and a volume approach. The computer program product is adapted to implement part or all of the steps of the method of the invention. The EAM system comprises computing navigation means implementing the method of the invention.

Classes IPC  ?

• G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
• G06T 7/00 - Analyse d'image
• G06T 7/11 - Découpage basé sur les zones
• G06T 7/187 - DécoupageDétection de bords impliquant des croissances de zonesDécoupageDétection de bords impliquant des fusions de zonesDécoupageDétection de bords impliquant un étiquetage de composantes connexes